[HTML][HTML] The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer
X Zhang, Y Feng, XY Wang, YN Zhang, CN Yuan… - Cell Death & …, 2018 - nature.com
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
X Zhang, Y Feng, XY Wang, YN Zhang… - Cell Death & …, 2018 - search.ebscohost.com
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer
X Zhang, Y Feng, W Xin-Yu, YN Zhang… - Cell Death and …, 2018 - search.proquest.com
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer
X Zhang, Y Feng, XY Wang, YN Zhang… - Cell death & …, 2018 - pubmed.ncbi.nlm.nih.gov
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
X Zhang, Y Feng, XY Wang, YN Zhang… - Cell Death & …, 2018 - europepmc.org
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
[HTML][HTML] The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer
X Zhang, Y Feng, XY Wang, YN Zhang… - Cell Death & …, 2018 - ncbi.nlm.nih.gov
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
X Zhang, Y Feng, XY Wang, YN Zhang… - Cell Death & …, 2018 - europepmc.org
Paclitaxel is widely used as a first-line chemotherapeutic drug for patients with ovarian
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …
cancer and other solid cancers, but drug resistance occurs frequently, resulting in ovarian …